Munson Health
 
Medications for Inflammatory Bowel Disease

Back to Document

by Wood D
 
The information provided here is meant to give you a general idea about each of the medicines listed below. Only the most general side effects are included. Ask your doctor if you need to take any special precautions. Use each of these medicines only as recommended by your doctor and according to the instructions provided. If you have further questions about usage or side effects, contact your doctor.
Medicines are prescribed to help control inflammation and other symptoms.

Prescription Medications

  • Sulfasalazine (Azulfidine)
  • Mesalamine (Asacol, Pentasa, Apriso, Lialda)
  • Balsalazide (Colazal)
  • Olsalazine (Dipentum)
  • Rectal administration forms (Rowasa enema, Canasa suppository)
  • Prednisone
  • Methylprednisolone
  • Budesonide (Entocort EC)
  • Azathioprine (Imuran)
  • 6-mercaptopurine (Purinethol)
  • Methotrexate (Folex)
  • Metronidazole (Flagyl)
  • Ampicillin (Amoxil)
  • Ciprofloxacin (Cipro)
  • Infliximab (Remicade)
  • Adalimumab (Humira)
  • Certolizumab Pegol (Cimzia)
  • Diphenoxylate-atropine (Lomotil)
  • Loperamide (Imodium)
  • Codeine
 

References


American Gastroenterological Association website. Available at: http://www.gastro.org. Accessed March 6, 2006.


Crohn's and Colitis Foundation of America website. Available at: http://www.ccfa.org. Accessed March 6, 2006.


Mosby's Drug Consult. Mosby, Inc.; 2002.


National Digestive Diseases Information Clearinghouse website. Available at: http://digestive.niddk.nih.gov. Accessed March 6, 2006.


Primary Care Medicine. 4th ed. Lippincott Williams and Wilkins; 2000.


Rakel RE and Bope ET. Conn's Current Therapy 2001. 53rd ed. Philadelphia, PA: W.B. Saunders Company; 2001.


10/2/2009 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php: FDA approves new drug to treat psoriasis. US Food and Drug Administration website. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm183851.htm. Published September 25, 2009. Accessed October 2, 2009.


12/3/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php: Zabana Y, Domènech E, Mañosa M, et al. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther. 2010;31:553-600.

 

Revision Information